Your browser doesn't support javascript.
loading
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Higgins, M; Curigliano, G; Dieras, V; Kuemmel, S; Kunz, G; Fasching, P A; Campone, M; Bachelot, T; Krivorotko, P; Chan, S; Ferro, A; Schwartzberg, L; Gillet, M; De Sousa Alves, P M; Wascotte, V; Lehmann, F F; Goss, P.
Afiliação
  • Higgins M; Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St., Dublin, 7, Ireland. mhiggins@mater.ie.
  • Curigliano G; Division of Early Drug Development, Istituto Europeo di Oncologia, Milan, Italy.
  • Dieras V; Clinical Investigational Unit, Institut Curie, Paris, France.
  • Kuemmel S; Breast UnitKliniken Essen-Mitte, Essen, Germany.
  • Kunz G; Department of Obstetrics & Gynecology, St.-Johannes-Hospital, Dortmund, Germany.
  • Fasching PA; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-EMN, Erlangen, Germany.
  • Campone M; Service d'Oncologie Médicale, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
  • Bachelot T; Department of Medical Oncology, Centre Leon Berard, Lyon, France.
  • Krivorotko P; Petrov Research Institute of Oncology, St. Petersburg, Russian Federation.
  • Chan S; Department of Clinical Oncology, Nottingham University Hospital NHS Trust (City campus), Nottingham, UK.
  • Ferro A; Unit of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
  • Schwartzberg L; Division of Hematology/Oncology, University of Tennessee Health Science Center, The West Clinic, Medical Oncology, Memphis, USA.
  • Gillet M; GSK Vaccines, Rixensart, Belgium.
  • De Sousa Alves PM; GSK Vaccines, Rixensart, Belgium.
  • Wascotte V; Celyad, Mont-Saint-Guibert, Belgium.
  • Lehmann FF; GSK Vaccines, Rixensart, Belgium.
  • Goss P; GSK Vaccines, Rixensart, Belgium.
Breast Cancer Res Treat ; 162(3): 479-488, 2017 04.
Article em En | MEDLINE | ID: mdl-28176175
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Vacinas Anticâncer / Proteínas WT1 Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Vacinas Anticâncer / Proteínas WT1 Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2017 Tipo de documento: Article